Who are Inderal's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Timolol 0.25% Ophthalmic Solution, Carvedilol CR, Empagliflozin + Carvedilol, RASi plus carvedilol, Carteolol long-acting ophthalmic solution, carvedilol immediate release.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/propranolol.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

Inderal — Competitive Intelligence Brief

Inderal (propranolol) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Non-selective beta-blocker. Area: Neuroscience.

marketed Non-selective beta-blocker Nuclear receptor subfamily 2 group E member 1, 5-hydroxytryptamine receptor 6, Cytochrome P450 1A2 Neuroscience Small molecule Live · refreshed every 30 min

Target snapshot

Inderal (propranolol) — Generic (originally ICI/AstraZeneca).

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Inderal TARGET	propranolol	Generic (originally ICI/AstraZeneca)	marketed	Non-selective beta-blocker	Nuclear receptor subfamily 2 group E member 1, 5-hydroxytryptamine receptor 6, Cytochrome P450 1A2	1967-11-13
Timolol 0.25% Ophthalmic Solution	Timolol 0.25% Ophthalmic Solution	Keith G. LeBlanc, Jr, MD	marketed	Beta-adrenergic antagonist (non-selective beta-blocker)	Beta-1 and beta-2 adrenergic receptors
Carvedilol CR	Carvedilol CR	University of Florida	marketed	Non-selective beta-blocker with alpha-1 blocking activity	Beta-1 adrenergic receptor, Beta-2 adrenergic receptor, Alpha-1 adrenergic receptor
Empagliflozin + Carvedilol	Empagliflozin + Carvedilol	Post Graduate Institute of Medical Education and Research, Chandigarh	marketed	SGLT2 inhibitor + non-selective beta-blocker combination	SGLT2 and beta-adrenergic receptors (β1, β2, α1)
RASi plus carvedilol	RASi plus carvedilol	Federal University of Minas Gerais	marketed	ACE inhibitor or ARB combined with non-selective beta-blocker	Angiotensin II receptor / ACE enzyme; beta-1 and beta-2 adrenergic receptors; alpha-1 adrenergic receptor
Carteolol long-acting ophthalmic solution	Carteolol long-acting ophthalmic solution	Otsuka Pharmaceutical Co., Ltd.	phase 3	Beta-adrenergic receptor antagonist (non-selective beta-blocker)	Beta-1 and beta-2 adrenergic receptors
carvedilol immediate release	carvedilol immediate release	CTI-1, LLC	phase 3	Non-selective beta-blocker	Beta-1 and beta-2 adrenergic receptors

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Non-selective beta-blocker class)

CTI-1, LLC · 1 drug in this class
Generic (originally ICI/AstraZeneca) · 1 drug in this class
GlaxoSmithKline · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Inderal — Competitive Intelligence Brief. https://druglandscape.com/ci/propranolol. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab